Next Science is excited to announce that 4 Poster Abstracts by key wound care experts have been accepted for presentation at the Spring Symposium on Advanced Wound Care. These presentations will highlight the benefits of products powered by Next Science’s patented, non-toxic Xbio™ technology to disrupt biofilm and treat chronic wounds. Read the Full Release
Next Science is excited to announce the results of a prospective, randomized 12-week Mayo Clinic study about the use of BlastX antimicrobial wound gel on chronic wounds to determine if disrupting chronic wound biofilm is therapeutically efficacious. The positive results are published in WOUNDS®. The study represents statistically significant findings for both reduction in wound … Read More
Next Science is pleased to announce the publication of a comprehensive article about the application of its Xbio technology to help prevent the development of E. coli biofilms on urinary tract catheters, a leading cause in catheter-associated urinary tract infections. The results are published in the Journal of Medical Microbiology & Diagnosis. View Publication Read … Read More
Next Science is proud to announce that Judith Mitchell has been appointed to its board of directors as Director and Chief Executive Officer. Ms. Mitchell joined Next Science in August 2017. Most recently she was President, DePuy Synthes Asia Pacific, the Orthopaedics Division of Johnson & Johnson.
Next Science will highlight its BlastX Antimicrobial Wound Gel at three upcoming conferences. It will exhibit at the Wild on Wounds National Wound Conference in Las Vegas, Nevada, from October 4-7. In addition to exhibiting, it will make poster presentations at SAWC Fall from October 19-22, also in Las Vegas. And Next Science will exhibit … Read More
Next Science’s proprietary BlastX Antimicrobial Wound Gel is highlighted in a recently published consensus paper on biofilm disruption and treatments. The novel Xbio™ technology in BlastX inhibits biofilm development by gram-positive and gram-negative wound pathogens.
Next Science is pleased to announce that Matthew Myntti, Ph.D., President and Director of R&D will be presenting “Advancing Biofilm Removal via Surgical Wound Lavage” at Montana State University’s Biofilm Science and Technology Meeting on July 20, 2017. Dr. Myntti’s presentation will highlight the collaborative development between Next Science and Zimmer Biomet on their Bactisure™ surgical lavage, an effective solution to the problem of biofilm in healing surgical wounds.
Leading wound care thought leaders have published a consensus on strategies for biofilm disruption and treatments. The peer-reviewed paper provides a new perspective regarding the need for a paradigm shift toward biofilm treatment strategies and disruption of the bacterial biofilm protective matrix. The publication was supported by Next Science.
Next Science and Zimmer Biomet have partnered with an exclusive global sales and distribution agreement for Bactisure™ Wound Lavage, a sterile, aqueous solution used to remove debris—including microorganisms—from wounds using pulsed (jet) lavage. Used as an adjunct to normal saline wound lavage, Bactisure has received FDA 510(k) clearance, and is available in 1000mL polypropylene bags with … Read More
Next Science is excited to announce new indications for its flagship product, BlastX™. BlastX is an antimicrobial wound gel powered by a patented, non-toxic technology that physically disrupts the biofilm matrix. As a result, bacteria within the gel are exposed and more vulnerable to attack by antimicrobials, antibiotics, and the body’s natural immune defenses. BlastX … Read More